FDA and regulatory approval risk
Transdermal drug products must clear lengthy regulatory review before commercialization.
- Scope
- Lead AVERSA product pipeline
- Materiality
- high
NutriBand Inc.
Nutriband Inc. is a U.S.-based pharmaceutical development and services company focused on transdermal drug-delivery products and abuse-deterrent patch technology. Through its subsidiaries, it also provides contract manufacturing and contract research and development services for health, wellness, pharmaceutical, and medical device customers.
−398,9 %
27,8 %
−404,1 %
−4,8 %
6.36
6.21
| % | |
|---|---|
| AVERSA transdermal products | 10% Development of abuse-deterrent patch-based drug delivery products using AVERSA technology. |
| Contract manufacturing | 70% Manufacturing services for health, wellness, OTC, topical, and transdermal products. |
| Contract R&D services | 20% Research and development services for pharmaceutical and medical device customers. |
Nutriband sells services to health and wellness, over-the-counter, pharmaceutical, and medical device customers, while...
- Health and wellness / OTC customersprimary
Buy contract manufacturing for transdermal, topical, and tape products.
- Pharmaceutical customersprimary
Use contract manufacturing and AVERSA-related development for drug patches.
- Medical device customerssecondary
Buy contract R&D services related to product development and testing.
- Drug-delivery partnersprimary
Collaborate on AVERSA-based transdermal products and clinical supply work.
Nutriband is headquartered in Orlando, Florida, and its manufacturing operations are centered in Cherryville, North...
- •Headquartered in Orlando, Florida
- •Manufacturing facility in Cherryville, North Carolina
- •Most revenue is generated in the United States
- •European investors participated in a private financing
- •U.S. regulatory exposure is central to product development
Nutriband's strategy centers on advancing AVERSA-based transdermal products through development and regulatory...
01
Advance AVERSA lead product developmentmedium-term
The platform is the core proprietary asset and the main long-term value driver.
02
Expand contract manufacturing utilizationshort-term
Manufacturing services provide operating revenue and support facility economics.
03
Maintain external development partnershipsmedium-term
Shared-cost collaborations reduce funding burden and add technical capability.
Nutriband faces development, regulatory, and funding risk because its lead products depend on FDA approval and...
Product safety and liability risk
Unexpected adverse events or misuse concerns could trigger recalls or enforcement.
- Scope
- Transdermal pharmaceutical products
- Materiality
- high
Financing and liquidity risk
Development-stage companies often need external capital to fund R&D and operations.
- Scope
- Corporate funding and product development
- Materiality
- high
Customer concentration and program dependence
Contract manufacturing and R&D revenue can be tied to a limited set of customers.
- Scope
- Pocono Pharmaceuticals and 4P Therapeutics
- Materiality
- medium
Revenue recognition under contracts with customers
Product sales are point-in-time; R&D services are recognized over time
Deferred revenue
Can shift revenue between periods
Going concern and liquidity estimates
Affects disclosure, investor perception, and capital structure analysis
Lease accounting
Impacts leverage and fixed-obligation analysis
R&D expense recognition
Suppresses near-term earnings while supporting pipeline investment
: 29.4.2026